María Luisa Peralta-Pedrero

María Luisa Peralta-Pedrero

Auto-generated profile, based on publicly available information

María Luisa Peralta-Pedrero

School of Medicine, Universidad Nacional Autónoma de México (UNAM), Av. Universidad 3000, Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2020 in JMIR Human Factors
Verified
Journal Article
Open access
MSMagdalena Del Rocio Sevilla-Gonzalez
Magdalena Del Rocio Sevilla-Gonzalez
LLLizbeth Moreno Loaeza
Lizbeth Moreno Loaeza
LLLaura Sofia Lazaro-Carrera
Laura Sofia Lazaro-Carrera
BRBrigette Bourguet Ramirez
Brigette Bourguet Ramirez
ARAnabel Vázquez Rodríguez
Anabel Vázquez Rodríguez
PAPaloma Almeda-Valdés
Paloma Almeda-Valdés
Background: The System Usability Scale (SUS) is a common metric used to assess the usability of a system, and it was initially developed in English. The implementation of electronic systems for clinical counseling (eHealth and mobile health) is increasing worldwide. Therefore, tools are needed to evaluate these applications in the languages and regional contexts in which the electronic tools are developed. Objective: This study aims to translate, culturally adapt, and validate the original English version of the SUS into a Spanish version. Methods: The translation process included forward and backward translation. Forward translations were made by 2 native Spanish speakers who spoke English as their second language, and a backward translation was made by a native English speaker. The Spanish SUS questionnaire was validated by 10 experts in mobile app development. The face validity of the questionnaire was tested with 10 mobile phone users, and the reliability testing was conducted among 88 electronic application users. Results: The content validity index of the new Spanish SUS was good, as indicated by a rating of 0.92 for the relevance of the items. The questionnaire was easy to understand, based on a face validity index of 0.94. The Cronbach α was .812 (95% CI 0.748-0.866; P<.001). Conclusions: The new Spanish SUS questionnaire is a valid and reliable tool to assess the usability of electronic tools among Spanish-speaking users.

20 March 2019 in Skin Appendage Disorders
Verified
Journal Article
Closed access
PDF file
RVRosalía del Carmen Vélez-Muñiz
Rosalía del Carmen Vélez-Muñiz
MPMaría Luisa Peralta-Pedrero
María Luisa Peralta-Pedrero
FCFermín Jurado-Santa Cruz
Fermín Jurado-Santa Cruz
MMMartha Alejandra Morales-Sánchez
Martha Alejandra Morales-Sánchez
Alopecia areata (AA) is a nonscarring alopecia with an autoimmune etiology, unpredictable course, multiple presentations, and variable psychological distress. We conducted a cross-sectional study which included 126 patients with AA. A complete medical history was documented using the Severity Alopecia Tool (SALT) to assess the severity of the disease, and the following questionnaires were applied to the participants: the Dermatology Life Quality Index (DLQI), Hospital Anxiety and Depression Scale (HADS), Plutchik Suicide Risk Scale, and the Perceived Stress Scale (PSS-14) for adults. The Child Dermatology Life Quality Index (cDLQI) and the Birleson Depression Self-Rating Scale questionnaires were applied for children. Quality of life (QoL) disturbance was detected in 77.6% of adult participants, 65.9% of them had signs of depression or anxiety, and 12.8% were at risk of committing suicide. The PSS-14 average score for adults was 24.5. QoL disturbance was detected in 76.7% of children participants, and 6.3% of them showed signs of depression with the Birleson Depression Self-Rating Scale. We conclude that patients with AA could experience changes in their QoL and signs of depression, anxiety, and suicide risk, mainly in the adult population, during the course of the disease.

20 July 2016 in Psychology and Psychotherapy: Theory, Research and Practice
Verified
Journal Article
Closed access
PDF file
ALABEL LERMA
ABEL LERMA
HPHéctor Perez‐Grovas
Héctor Perez‐Grovas
Luis Bermudez HumaránLuis Bermudez Humarán
Luis Bermudez Humarán
MPMaría L. Peralta‐Pedrero
María L. Peralta‐Pedrero
RRRebeca Robles‐García
Rebeca Robles‐García
Claudia LermaClaudia Lerma
Claudia Lerma

5 March 2022 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
BABerenice Araiza-Nava
Berenice Araiza-Nava
LMLucía Méndez-Sánchez
Lucía Méndez-Sánchez
PCPatricia Clark
Patricia Clark
MPMaría Luisa Peralta-Pedrero
María Luisa Peralta-Pedrero
MJMuhammad Kassim Javaid
Muhammad Kassim Javaid
FGFabiola Guzmán-Jiménez
Fabiola Guzmán-Jiménez

19 February 2014 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
MOMaría Guadalupe Olguin-García
María Guadalupe Olguin-García
FCFermín Jurado-Santa Cruz
Fermín Jurado-Santa Cruz
MPMaría Luisa Peralta-Pedrero
María Luisa Peralta-Pedrero
MMMartha Alejandra Morales-Sánchez
Martha Alejandra Morales-Sánchez
Background: Recalcitrant facial flat warts are caused by human papillomavirus and may persist for years despite treatment. Isotretinoin has demonstrated benefits in the treatment of recalcitrant, genital and common warts, but placebo-controlled trials have not been performed. To determine whether isotretinoin is safe and effective for recalcitrant facial flat warts. Isotretinoin 30 mg/day or placebo was administered to 16 and 15 patients, respectively, in double-blind, randomized fashion for 12 weeks. Cutaneous lesions were assessed and adverse events including serologic and ophthalmologic changes were recorded. It is considered that warts were recalcitrant if the patient was treated for at least 3 years with at least three of the following options: retinoids, 5-fluorouracil, imiquimod and cryotherapy using liquid nitrogen. Each patient in the istotretinoin group showed complete clearance of all flat warts, while none of the patients in the placebo group showed any improvement (p=0.0001). The most frequent adverse event was cheilitis. There were no statistically significant changes in the laboratory findings. The study design does not permit complete blinding of the dermatologist who can easily recognize the adverse effects of isotretinoin. The clinical findings, however, were so dramatic that this would not have impacted the findings. Another limitation of the study is a lack of follow-up to assess for recurrence after the drug was discontinued. Isotretinoin is an effective treatment for recalcitrant flat facial warts with a well-known, manageable safety profile.

1 September 2017 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Closed access
MMMartha Alejandra Morales-Sánchez
Martha Alejandra Morales-Sánchez
MVM. Vargas-Salinas
M. Vargas-Salinas
MPM.L. Peralta-Pedrero
M.L. Peralta-Pedrero
MOM.G. Olguín-García
M.G. Olguín-García
FCF. Jurado-Santa Cruz
F. Jurado-Santa Cruz